Biofil Chemicals and Pharmaceuticals Ltd
BIOFILCHEMBiofil Chemicals and Pharmaceuticals Ltd
BIOFILCHEMPrice Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
188.90 | 5.29 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
50.26 | 6.38 | 0.53% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Biofil Chemicals and Pharmaceuticals Limited is engaged in pharmaceuticals and chemicals business. The Company is also engaged in manufacturing plastic products for the purpose of packing of pharmaceutical product and other plastic products.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 13.70 | 13.59 | 12.46 | 23.23 | 29.86 | 36.55 | 22.53 | 30.14 | 40.53 | 31.57 | ||||||||||
Raw Materials | 10.54 | 8.52 | 10.69 | 19.82 | 25.65 | 35.20 | 15.87 | 27.62 | 37.78 | 30.51 | ||||||||||
Power & Fuel Cost | 0.37 | 0.44 | 0.33 | 0.37 | 0.49 | 0.29 | 0.30 | 0.33 | 0.38 | |||||||||||
Employee Cost | 0.48 | 0.53 | 0.73 | 0.89 | 0.86 | 0.75 | 0.79 | 0.45 | 0.50 | |||||||||||
Selling & Administrative Expenses | 0.39 | 0.86 | 0.53 | 0.72 | 0.78 | 0.37 | 0.37 | 0.54 | 0.56 | |||||||||||
Operating & Other expenses | 0.53 | 0.48 | -0.86 | 0.30 | 0.09 | -2.46 | 3.72 | -0.08 | 0.00 | |||||||||||
EBITDA | 1.39 | 2.76 | 1.04 | 1.13 | 1.99 | 2.40 | 1.48 | 1.28 | 1.31 | 1.06 | ||||||||||
Depreciation/Amortization | 0.26 | 0.28 | 0.30 | 0.37 | 0.41 | 0.41 | 0.43 | 0.43 | 0.40 | 0.39 | ||||||||||
PBIT | 1.13 | 2.48 | 0.74 | 0.76 | 1.58 | 1.99 | 1.05 | 0.85 | 0.91 | 0.67 | ||||||||||
Interest & Other Items | 0.15 | 0.16 | 0.15 | 0.16 | 0.12 | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | ||||||||||
PBT | 0.98 | 2.32 | 0.59 | 0.60 | 1.46 | 1.92 | 1.01 | 0.81 | 0.87 | 0.63 | ||||||||||
Taxes & Other Items | 0.20 | 0.52 | 0.12 | 0.12 | 0.26 | 0.67 | 0.32 | 0.23 | 0.15 | 0.12 | ||||||||||
Net Income | 0.78 | 1.80 | 0.47 | 0.48 | 1.20 | 1.25 | 0.69 | 0.58 | 0.72 | 0.51 | ||||||||||
EPS | 0.48 | 1.11 | 0.29 | 0.29 | 0.74 | 0.77 | 0.42 | 0.36 | 0.44 | 0.31 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Biofil Chemicals and Pharmaceuticals Ltd | 133.81 | 5.29 | — |
Sun Pharmaceutical Industries Ltd | 44.98 | 6.42 | 0.75% |
Cipla Ltd | 29.13 | 4.48 | 0.87% |
Torrent Pharmaceuticals Ltd | 64.71 | 15.63 | 0.88% |
Price Comparison
Compare BIOFILCHEM with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
BIOFILCHEM has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Net profit of Biofil Chemicals & Pharmaceuticals declined 83.33% to Rs 0.02 crore in the quarter ended September 2024 as against Rs 0.12 crore during the previous quarter ended September 2023. Sales declined 86.13% to Rs 2.41 crore in the quarter ended September 2024 as against Rs 17.37 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2.4117.37 -86 OPM %4.981.38 - PBDT0.130.26 -50 PBT0.030.15 -80 NP0.020.12 -83 Powered by Capital Market - Live
Biofil Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Biofil Chemicals & Pharmaceuticals announced that the 39th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Net profit of Biofil Chemicals & Pharmaceuticals declined 29.17% to Rs 0.17 crore in the quarter ended June 2024 as against Rs 0.24 crore during the previous quarter ended June 2023. Sales rose 247.33% to Rs 8.44 crore in the quarter ended June 2024 as against Rs 2.43 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales8.442.43 247 OPM %3.6717.28 - PBDT0.330.43 -23 PBT0.230.32 -28 NP0.170.24 -29 Powered by Capital Market - Live
Biofil Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
Bharat Immunological & Biological Corporation Ltd leads gainers in ‘B’ group
STL Global Ltd leads losers in ‘B’ group
Biofil Chemicals & Pharmaceuticals Ltd leads gainers in ‘B’ group
Keynote Financial Services Ltd leads gainers in ‘B’ group
Biofil Chemicals & Pharmaceuticals Ltd leads gainers in ‘B’ group
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 11.78%, vs industry avg of 9.03%
Constant Market Share
Over the last 5 years, market share stayed at 0.01%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 8.45%, vs industry avg of 15.28%